2016-08-18
Ark Biosciences Initiates VICTOR Study
Ark Biosciences announced that dosing with AK0529, its leading antiviral drug against respiratory syncytial virus (RSV), has commenced in infants hospitalized with RSV infection in the VICTOR study.
know more >